April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
CD147 Expression Required for Corneal Lactate Efflux
Author Affiliations & Notes
  • Shimin Li
    School of Optometry, Indiana University, Bloomington, IN
  • Tracy Thuy Nguyen
    College of Optometry, State University of New York, New York, NY
  • Joseph A Bonanno
    School of Optometry, Indiana University, Bloomington, IN
  • Footnotes
    Commercial Relationships Shimin Li, None; Tracy Nguyen, None; Joseph Bonanno, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2030. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shimin Li, Tracy Thuy Nguyen, Joseph A Bonanno; CD147 Expression Required for Corneal Lactate Efflux. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2030.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: CD147 acts as a chaperone protein to facilitate the expression and membrane trafficking of monocarboxylate (e.g., lactate) transporters, MCT1 and MCT4. Lactate:H+ efflux is a significant component of the endothelial pump. Therefore we expect corneal edema and diminished pump capacity in corneas with reduced CD147 expression. Previously, we found that CD147 is required for corneal lactate efflux and maintenance of endothelial cell pH in ex vivo rabbit corneas. In this study, we conducted animal experiments to confirm these findings.

Methods: CD147 expression was knocked down via Lentiviral vector facilitated shRNA transfection. Pseudoviral particles of Lenti-shRNA-CD147 were injected into the anterior chamber of NZW rabbit eyes (OD) and Lenti-shRNA-luciferase was injected into left eyes (OS), n=5. Corneal thickness was measured by SD-OCT for up to 4 weeks post-injection. An Azopt stress test (two drops of 1% Brinzolamide suspension, a carbonic anhydrase inhibitor) was performed at two weeks post-injection. Animals were euthanized and endothelium dissected for western blot of CD147 and MCTs. Cornea stroma-epithelium was analyzed for [lactate].

Results: A preliminary dose trial indicated that 5x106 IFU titer of lenti-shRNA particles was most effective in knocking down the expression of CD147, MCT1 and MCT4 in corneal endothelium. Significant differences in central corneal thickness were observed between control and KD eyes at 6 days post-injection and Lenti-shRNA-CD147 eyes were 24µm thicker than paired control corneas by 3 weeks (p<0.05). Peak corneal swelling following Brinzolamide application (3 hours) was 12.0µm (3.3% swelling) in control and 24.4µm (6.5% swelling) in Lenti-shRNA-CD147 transfected corneas. Lactate concentration was 47.95 ± 2.1 nmol/mg dry cornea tissue in the KD and 17.75 ± 1.09 nmol/mg in the control corneas (p<0.05). Western blot showed that CD147 was reduced by 67% ± 0.03, MCT1 by 60% ± 0.06 and MCT4 by 55% ± 0.11 in KD corneas. MCT2 was not changed.

Conclusions: CD147 is required for MCT1 and MCT4 expression in corneal endothelium in vivo. Knockdown slows lactate efflux leading to corneal edema, reduced endothelial pump capacity, and increased corneal lactate concentrations, consistent with lactate efflux being a significant contributor to the corneal endothelial pump.

Keywords: 481 cornea: endothelium • 570 ion transporters • 533 gene/expression  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.